within Pharmacolibrary.Drugs.ATC.M;

model M02AA06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.21,
    Cl             = 0.175 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Etofenamate is a nonsteroidal anti-inflammatory drug (NSAID) in the class of anthranilic acid derivatives. It is used topically for the treatment of musculoskeletal pain and inflammation, such as in osteoarthritis, sports injuries, and soft tissue rheumatism. Etofenamate is commonly available in gel or cream form for dermal application. It is approved and in clinical use in several European and Asian countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adult volunteers after topical administration of etofenamate gel 5%, assessed by systemic absorption and plasma pharmacokinetics.</p><h4>References</h4><ol><li><p>Marto, J, et al., &amp; Ribeiro, HM (2015). Topical gels of etofenamate: in vitro and in vivo evaluation. <i>Pharmaceutical development and technology</i> 20(6) 710–715. DOI:<a href=&quot;https://doi.org/10.3109/10837450.2014.915571&quot;>10.3109/10837450.2014.915571</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24798887/&quot;>https://pubmed.ncbi.nlm.nih.gov/24798887</a></p></li><li><p>Drago, S, et al., &amp; Drewe, J (2017). Pharmacokinetics of Transdermal Etofenamate and Diclofenac in Healthy Volunteers. <i>Basic &amp; clinical pharmacology &amp; toxicology</i> 121(5) 423–429. DOI:<a href=&quot;https://doi.org/10.1111/bcpt.12818&quot;>10.1111/bcpt.12818</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28561421/&quot;>https://pubmed.ncbi.nlm.nih.gov/28561421</a></p></li><li><p>Bender, T, et al., &amp; Bálint, G (2001). Etofenamate levels in human serum and synovial fluid following iontophoresis. <i>Arzneimittel-Forschung</i> 51(6) 489–492. DOI:<a href=&quot;https://doi.org/10.1055/s-0031-1300068&quot;>10.1055/s-0031-1300068</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11455681/&quot;>https://pubmed.ncbi.nlm.nih.gov/11455681</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M02AA06;
